Testing a new cancer treatment for advanced head and neck tumors

Plain-English translation of NCT06469008 on ClinicalTrials.gov ↗ · Source last updated September 2025 · Translation generated July 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This is an early-stage clinical trial (Phase I) testing a new medication called in patients with advanced head and neck cancer or other solid tumors that have returned or spread despite standard treatment. The trial will evaluate whether the medication is safe to use, what side effects it causes, and whether it helps shrink tumors. About 21 patients will participate across multiple hospitals.

Patients with recurrent or metastatic head and neck cancer often have few options after standard treatments fail. This medication is being tested to see if it offers a new treatment path for these patients and to understand how it works in the human body.

Do you qualify?

You likely qualify if…

you are between 18 and 75 years old (or 18+ in certain parts of the trial)
you have been diagnosed with advanced head and neck cancer that has returned or spread, or another advanced solid tumor, and standard treatments haven't worked or aren't available
you have at least one tumor that can be measured on imaging scans
you are in generally good health with an expected survival of at least 3 months
your heart function is normal or near-normal, with an ejection fraction of at least 50%
any side effects from previous cancer treatments have resolved to mild levels

You likely don't qualify if…

you have received cancer treatment within the last 4 weeks (or 6 weeks for certain older chemotherapy drugs)
you have a history of severe heart disease, abnormal heart rhythms, or uncontrolled high blood pressure despite medication
you have active autoimmune disease, uncontrolled diabetes, or active lung inflammation from prior radiation
you have had another cancer diagnosis within the past 5 years
you are allergic to antibody-based medications or any ingredients in this new treatment

What participation looks like

You will receive the new medication as an intravenous infusion (through a vein) during a 3-week cycle. If the treatment is helping and you tolerate it well, you may continue to receive additional cycles. Throughout the trial, you'll have regular blood tests, imaging scans, and check-ups to monitor how the medication is working and watch for any side effects. The trial will stop if your cancer progresses, if side effects become too severe, or for other medical reasons.

AI-generated summary from trial data · Jul 15, 2026 · Not medical advice

Trial locations(1 site)

China

Shanghai East Hospital, Shanghai, Shanghai Municipality